A securities class action lawsuit has been filed against InfuSystem Holding. (NYSE: INFU) in connection to allegations that the company violated securities law from May 12, 2015 through November 7, 2016. Fitapelli Kurta is interested in hearing from aggrieved shareholders of InfuSystem Holdings (INFU) who may want to participate as a lead plaintiff in the pending securities class action lawsuit.
The complaint alleges that InfuSystem Holdings (INFU) falsely or misleadingly represented, and/or failed to disclose, that it did not possess adequate internal control over the internal reporting of finances; that its financial statements, dating to the beginning of 2015, contained overstatements of accounts receivables collections, as well as corresponding overstatements of pre-tax income and revenues; that these financial statements were then unreliable; and that thus InfuSystem Holdings (INFU) made false or misleading representations of its financial statements during the relevant period.
According to the company’s website, InfuSystem Holdings “is a growing healthcare company that provides infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from five locations serving all 50 States and Canada. We deliver improved patient outcomes and high patient satisfaction.” InfuSystem Holdings (INFU) provides ambulatory pumps and supplies, clinical support, catheter care kits, EMR integration, and asset management. It is headquartered in Madison, Wisconsin and trades on the New York Stock Exchange under the symbol INFU.
A class action lawsuit has already been filed in connection with INFU. If you wish to serve as lead plaintiff in the InfuSystem Holdings lawsuit, you must move the Court no later than January 9, 2017. If you wish to join the litigation, please contract Marc Fitapelli at 212-658-1501 or Jonathan Kurta at 212-658-1502. There is no cost or obligation to you and your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.